Why Good Records Management Is Key - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Why Good Records Management Is Key


Pharmaceutical Technology Europe
Volume 23, Issue 10


Karen Redding. Global business development director at Phlexglobal Ltd.
The past year has seen significant consolidation of mid-size CROs, with many of them being bought or put up for sale. In particular, the top six or seven CROs seem to be signing more preferred partner deals, such as Pfizer teaming with Parexel and ICON, and Takeda’s deals with Covance and Quintiles, which is driving mid-size CROs growth through major acquisitions. There has also been a big shift in outsourcing services to preferred partnerships, with large CROs outsourcing niche services to small CROs on a functional basis. Sponsors are also assessing their current tasks and outsourcing those that require non-core expertise. One niche area that companies do not always consider outsourcing is document control. Document management is essential in the pharma industry but can be difficult to optimise, so working with an outsourcing partner can be valuable.

Good records management

Good records management is crucial in the pharma industry. One of the most common problems we see is individuals and teams retaining their own copy of documents rather than utilising a single central source, preferably made available via an electronic document management system (EDMS). In our highly regulated environment, demonstrating the reliability and authenticity of documentation is critical, so individuals making use of a central definitive source for their records is particularly important. In addition, much time and money is wasted through duplication and mismanagement of documents when carried out in an uncontrolled manner.

In some industry sectors, management have introduced strict controls over where and how documents may be saved. Some organisations, for example, prevent documents from being saved anywhere except in an authorised EDMS. Perhaps this is one step too far, but good document control is necessary to achieve regulatory compliance.


Eldin Rammell. Managing director at Rammell Consulting Ltd, a sub-contractor of Phlexglobal Ltd.
Another problem we often see is poor version control, particularly for draft documents. As there may be a need to demonstrate appropriate review of draft documents, it is essential that any review signatures and comments be unambiguously linked to the associated document. This requires a formal system of version control within the organisation.

Once a pharmaceutical process has been completed—whether a clinical trial or the production of a batch of drugs—the only thing remaining to demonstrate regulatory compliance is the documentation audit trail. This is why adequate quality control is so important. It is not enough just to have a record of what happened; regulatory authorities have an expectation that you can demonstrate those records to be accurate, legible, contemporaneous, original, attributable, complete, consistent, enduring and available when needed (1). A well-designed quality system will ensure that documentation being sent off to the archive is “fit for purpose”.

Poor quality control can be recognised when a sponsor is notified of an impending regulatory inspection. All too often, there is a mad panic as documentation is retrieved from various filing systems and hours are spent checking files for completeness. This is wasted effort and diverts key personnel from their core activities. A robust quality control system should eliminate the need for these eleventh-hour activities and result in inspection-ready files. Furthermore, quality control should ideally be embedded within existing processes rather than being introduced as an additional process. It is better to prevent poor quality records from being generated rather than identifying poor quality records and having to expend effort in fixing them.

The vast majority of regulatory requirements worldwide actually say very little about records management, which has been a bone of contention for years. On the one hand, records management professionals prefer the need for explicit guidance so that there is assurance they are operating within the permitted boundaries, but on the other hand, the lack of explicit guidance gives freedom to define company-specific processes and systems. However, it would be helpful for regulators to provide more specific guidelines in areas that are troubling industry the most, particularly where they see commonly occurring inspection deficiencies.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here